<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-130662" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tumor Treatment Fields in Oncology</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Katiyar</surname>
            <given-names>Varidh</given-names>
          </name>
          <aff>All India Institute of Medical Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>De Jesus</surname>
            <given-names>Orlando</given-names>
          </name>
          <aff>University of Puerto Rico, Medical Sciences Campus, Neurosurgery Section</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Varidh Katiyar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Orlando De Jesus declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-130662.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Tumor treatment fields (TTF) are a recent addition to the arsenal in our fight against cancer and have shown promising initial results. Unlike other cancer treatment modalities, it is associated with minimal side effects. This activity reviews the mechanism of action and the role of TTF against various neoplastic conditions and highlights the role of the interprofessional team in the management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the role of TTF in the management of neoplastic conditions.</p></list-item><list-item><p>Outline the mechanism of action of electric fields in inhibiting cell division.</p></list-item><list-item><p>Summarize the indications and the current evidence for each of them.</p></list-item><list-item><p>Review the contraindications and side effects of TTF observed by the interprofessional team.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=130662&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=130662">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-130662.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>One of the leading causes of death worldwide is cancer.<xref ref-type="bibr" rid="article-130662.r1">[1]</xref> Most of the traditional cancer treatment modalities are associated with significant adverse events. With a greater understanding of the pathophysiology of carcinogenesis and mechanisms underlying resistance to different treatments, we are slowly adding novel treatment modalities to our arsenal to fight cancer.</p>
        <p>One of these novel therapeutic strategies applies intermediate frequency, low intensity, alternating electrical fields that produce antineoplastic activity. These electric fields are delivered&#x000a0;noninvasively to the tumor location using ceramic transducer arrays, which exert an inhibitory effect over cell division.<xref ref-type="bibr" rid="article-130662.r2">[2]</xref><xref ref-type="bibr" rid="article-130662.r3">[3]</xref>&#x000a0;Tumor treatment fields (TTF) have been approved by the US Food and Drug Administration (FDA) as adjuvant therapy for newly diagnosed and recurrent&#x000a0;glioblastoma.</p>
      </sec>
      <sec id="article-130662.s3" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>
<bold>Physical Principles</bold>
</p>
        <p>The role of the macromolecules and organelles involved in the process of cell division is critically dependent on the polar nature of these molecules. Their appropriate location in the cell and movement in a definite pattern according to the cell cycle stage is important for cell division to happen. Application of external alternating electrical fields interferes with this coordinated natural movement of these electrically sensitive polar macromolecules disrupting mitosis. The following two effects of electric fields on these macromolecules are responsible for the negative impact on cell division:</p>
        <p><bold>1. Effect on Alignment</bold>: Any molecule with spatial separation of the positive and negative charges is called a dipole and is sensitive to experiencing differential forces in the presence of an external electric field. Such molecules are forced to align along the direction of the local electric field, which prevents them from attaining the appropriate alignment required for mitosis to progress. This dipole alignment effect is predominant on the random movement of tubulin protein and prevents its polymerization by inhibiting the formation of the mitotic spindle. This effect results in metaphase arrest.<xref ref-type="bibr" rid="article-130662.r4">[4]</xref></p>
        <p><bold>2. Effect on Location</bold>: These polar macromolecules also tend to concentrate in regions of high electric field density in the presence of non-uniform electric fields. The various factors that result in a non-uniform distribution of electrical fields are the geometry and the differential electrical property of the tissue. This displaces them from the specific spatial location in the cell they are supposed to be in the particular stage of the cell cycle.<xref ref-type="bibr" rid="article-130662.r5">[5]</xref>&#x000a0;</p>
        <p>This process, called dielectrophoresis, primarily affects the spatial location of the septin protein complex, which migrates to the constricted center of the dividing cell during the telophase due to high electric fields in that region due to the hourglass shape of the dividing cell. These electric fields exert minimal effects on normal tissue with a lower proliferative rate. Skin tissue surrounding the region may experience side effects because of a relatively higher turnover rate. There is some evidence that TTF may also cause alteration to oncogenes like p53.<xref ref-type="bibr" rid="article-130662.r6">[6]</xref> The use of nanoparticles along with TTF has also been shown to have synergistic anti-neoplastic action.<xref ref-type="bibr" rid="article-130662.r7">[7]</xref></p>
      </sec>
      <sec id="article-130662.s4" sec-type="Indications">
        <title>Indications</title>
        <p>TTF has been studied for several solid organ malignancies and has received approval for use in primary and recurrent glioblastoma alone and in combination with other adjuvant therapies. The indications for the use of TTF and the current evidence are summarized below.</p>
        <p>
<bold>Glioblastoma</bold>
</p>
        <p>Glioblastoma is the most dangerous primary malignant brain tumor and has the worst prognosis.&#x000a0;It is also the most common primary brain malignancy with an incidence rate of 3.2 to 4.5 per 100,000 individuals.<xref ref-type="bibr" rid="article-130662.r8">[8]</xref> Despite significant advances in its treatment options, it still has a grim survival rate. Regardless of the treatment, recurrence in&#x000a0;glioblastoma remains a major problem. Moreover, an effective treatment strategy for recurrent&#x000a0;glioblastoma has not been found yet.<xref ref-type="bibr" rid="article-130662.r9">[9]</xref></p>
        <p>TTF has emerged as a potential treatment option in&#x000a0;glioblastoma due to its locally invasive nature and decreased propensity to metastasize to distant organs facilitating maximum coverage of the tumor-containing region. TTF was approved by the FDA for use in recurrent glioblastoma in 2011, followed by newly diagnosed glioblastoma in 2015. The median progression-free survival increased from 4 months to 7.1 months, while the median overall survival increased from 16 months to 20.9 months with the addition of TTF to maintenance temozolomide in a randomized clinical trial by Stupp et al. in 2017.<xref ref-type="bibr" rid="article-130662.r10">[10]</xref> Additionally, it is safer to use TTF in&#x000a0;glioblastoma as the brain does not contain non-cancerous dividing cells, unlike other organs.<xref ref-type="bibr" rid="article-130662.r3">[3]</xref><xref ref-type="bibr" rid="article-130662.r11">[11]</xref></p>
        <p>
<bold>Pancreatic Cancer&#x000a0;</bold>
</p>
        <p>The utility of TTF is also being studied in pancreatic cancer, particularly advanced-stage carcinomas, due to its antiproliferative effects in preclinical trials. The replicability of these effects is being studied in an ongoing clinical trial, PANOVA, in which patients with pancreatic adenocarcinoma received either TTF along with gemcitabine or gemcitabine and nab-paclitaxel.</p>
        <p><bold>Ovarian Cancer</bold>&#x000a0;</p>
        <p>TTF has also gained popularity in the treatment of recurrent ovarian cancer, and one such trial, INNOVATE, focuses on the safety and feasibility of TTF in combination with paclitaxel.</p>
        <p>
<bold>Non-small Cell Lung Carcinoma</bold>
</p>
        <p>The efficacy of TTF has been shown in animal models of advanced non-small cell lung carcinoma. Human studies have demonstrated the safety of the treatment, but its efficacy is still under evaluation. Ongoing LUNAR phase III trial aims to evaluate the efficacy of TTF with docetaxel in non-small cell lung carcinoma.</p>
        <p><bold>Malignant Mesothelioma</bold>&#x000a0;</p>
        <p>The use of TTF in combination with pemetrexed and cisplatin or carboplatin in unresectable or metastatic mesothelioma has been FDA approved as the first-line treatment. A chest applicator has been developed to deliver TTF to the thoracic cavity. The side effects include mild to moderate dermatitis in about half of the patients.</p>
        <p>
<bold>Future Role of TTF</bold>
</p>
        <p>It is being evaluated in preclinical studies in several other malignancies, including breast carcinoma, urogenital malignancies, renal carcinoma, colorectal carcinoma, and hepatocellular carcinoma. Another avenue of further development is dose and delivery optimization which may further increase the list of indications. Long-term adverse effects and the impact of alternating electric fields on healthy tissue are also a matter of further research.</p>
      </sec>
      <sec id="article-130662.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are no absolute contraindications to the use of TTF. Though the manufacturer doesn&#x02019;t recommend the use of TTF among patients with implanted medical devices like pacemakers, deep brain stimulation electrodes, etc., a study found no adverse effect of TTF in such patients. A pre-existing skin disorder may be considered a relative contraindication as TTF itself may cause allergic or contact dermatitis, resulting in its exacerbation.</p>
      </sec>
      <sec id="article-130662.s6" sec-type="Equipment">
        <title>Equipment</title>
        <p>The TTF device consists of an electric field generator to generate electric fields and transducer arrays to deliver a particular electric field configuration to the patient. The electric field generator sits in a backpack that the patient can carry while going on with the daily activities. The lithium-ion battery in the device should be charged overnight, and the transducer coils are supposed to be changed every 3&#x000a0;or 4 days. For patients with glioblastoma, the scalp hair needs to be removed for proper contact between the transducer arrays and the scalp.</p>
      </sec>
      <sec id="article-130662.s7" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>The TTF delivery is tailored to the tumor's size, shape, and location.<xref ref-type="bibr" rid="article-130662.r12">[12]</xref> The configuration in which the arrays are to be applied externally is individualized using proprietary software to achieve maximum field at the tumor target. The factors used for this calculation include morphometry and the specific location of the tumor.<xref ref-type="bibr" rid="article-130662.r13">[13]</xref> Additionally, the intensity and direction of the electric field at all points can also be simulated. Such simulations can further help tailor the array configuration used for a particular patient.</p>
      </sec>
      <sec id="article-130662.s8" sec-type="Complications">
        <title>Complications</title>
        <p>The adverse effects of TTF are limited to mild to moderate dermatological complications like dermatitis in the region of the application of transducer arrays. The longest follow-up data is available for patients with&#x000a0;glioblastoma treated with TTF, and the rate of dermatitis ranges from 16 to 43%. This complication has been seen around 2 to 6 weeks after the initiation of treatment in patients with glioblastoma. Dermatitis is usually easily controlled with topical steroids and antibiotics, oral antibiotics, and local skin protection.<xref ref-type="bibr" rid="article-130662.r14">[14]</xref></p>
        <p>However, compliance with the therapy is generally found to be high. It attests to the safety of this treatment modality, at least for the limited duration of follow-up available. The long-term effects and complications of TTF will be known as more literature is available in the future.</p>
      </sec>
      <sec id="article-130662.s9" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>The long-term outcomes of TTF are still not available, but the initial results have shown promise. TTF has been FDA approved for use in recurrent&#x000a0;glioblastoma, and ongoing trials may establish its role in not only primary&#x000a0;glioblastoma but other malignancies like pancreatic cancer, ovarian cancer, non-small cell lung carcinoma, and mesothelioma. It may also play a role in modulating the effect of currently accepted treatment modalities like chemotherapy, radiotherapy, and immunotherapy. The fine-tuning of physical parameters involved in TTF with further research on TTF dosimetry is likely to enhance the impact of this novel modality in cancer therapeutics.</p>
      </sec>
      <sec id="article-130662.s10" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>TTF is a new treatment modality for neoplastic diseases that utilizes low intensity, intermediate-frequency alternating electric fields to produce anti-mitotic activity. It has been approved for the treatment of recurrent&#x000a0;glioblastoma alone and in combination with chemotherapy and radiotherapy, in which it may have a synergistic action. Its role in several other malignancies is the subject of many ongoing clinical trials. It is a relatively safe treatment with minimal side effects limited to locoregional skin tissue in the form of dermatitis.&#x000a0;</p>
        <p>Management of patients with malignancy requires the involvement of professionals from multiple disciplines like the specific surgical specialty, surgical oncology, radiation oncology, medical oncology, palliative care, and nursing staff.</p>
      </sec>
      <sec id="article-130662.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=130662&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=130662">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/130662/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=130662">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-130662.s12">
        <title>References</title>
        <ref id="article-130662.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cancer Statistics, 2021.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>71</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-33</page-range>
            <pub-id pub-id-type="pmid">33433946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130662.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirson</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Gurvich</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Schneiderman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dekel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Itzhaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wasserman</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Schatzberger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Palti</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Disruption of cancer cell replication by alternating electric fields.</article-title>
            <source>Cancer Res</source>
            <year>2004</year>
            <month>May</month>
            <day>01</day>
            <volume>64</volume>
            <issue>9</issue>
            <fpage>3288</fpage>
            <page-range>3288-95</page-range>
            <pub-id pub-id-type="pmid">15126372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130662.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stupp</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Kanner</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Engelhard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Heidecke</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kirson</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Taillibert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liebermann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dbal&#x000fd;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ram</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Villano</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Rainov</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Weinberg</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kunschner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Raizer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Honnorat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sloan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malkin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Landolfi</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Payer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mehdorn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weil</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Pannullo</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Westphal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smrcka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kostron</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hofer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bruce</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cosgrove</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Paleologous</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Palti</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gutin</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.</article-title>
            <source>Eur J Cancer</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>48</volume>
            <issue>14</issue>
            <fpage>2192</fpage>
            <page-range>2192-202</page-range>
            <pub-id pub-id-type="pmid">22608262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130662.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gutin</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>ET</given-names>
              </name>
            </person-group>
            <article-title>Noninvasive application of alternating electric fields in glioblastoma: a fourth cancer treatment modality.</article-title>
            <source>Am Soc Clin Oncol Educ Book</source>
            <year>2012</year>
            <fpage>126</fpage>
            <page-range>126-31</page-range>
            <pub-id pub-id-type="pmid">24451721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130662.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gera</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Holtzman</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SX</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>e0125269</fpage>
            <pub-id pub-id-type="pmid">26010837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130662.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Baek</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>EH</given-names>
              </name>
            </person-group>
            <article-title>Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment.</article-title>
            <source>Sci Rep</source>
            <year>2020</year>
            <month>Jul</month>
            <day>23</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>12272</fpage>
            <pub-id pub-id-type="pmid">32704022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130662.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fr&#x000f6;hlich</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles.</article-title>
            <source>Int J Nanomedicine</source>
            <year>2012</year>
            <volume>7</volume>
            <fpage>5577</fpage>
            <page-range>5577-91</page-range>
            <pub-id pub-id-type="pmid">23144561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130662.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ostrom</surname>
                <given-names>QT</given-names>
              </name>
              <name>
                <surname>Gittleman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fulop</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blanda</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kromer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wolinsky</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kruchko</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barnholtz-Sloan</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.</article-title>
            <source>Neuro Oncol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>17 Suppl 4</volume>
            <issue>Suppl 4</issue>
            <fpage>iv1</fpage>
            <page-range>iv1-iv62</page-range>
            <pub-id pub-id-type="pmid">26511214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130662.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campos</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Urup</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Poulsen</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>A comprehensive profile of recurrent glioblastoma.</article-title>
            <source>Oncogene</source>
            <year>2016</year>
            <month>Nov</month>
            <day>10</day>
            <volume>35</volume>
            <issue>45</issue>
            <fpage>5819</fpage>
            <page-range>5819-5825</page-range>
            <pub-id pub-id-type="pmid">27041580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130662.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stupp</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Taillibert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kanner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Read</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lhermitte</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Toms</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Idbaih</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahluwalia</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Di Meco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lieberman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Stragliotto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brem</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hottinger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kirson</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Lavy-Shahaf</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Weinberg</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Paek</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Nicholas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bruna</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hirte</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Weller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Palti</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hegi</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Ram</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2017</year>
            <month>Dec</month>
            <day>19</day>
            <volume>318</volume>
            <issue>23</issue>
            <fpage>2306</fpage>
            <page-range>2306-2316</page-range>
            <pub-id pub-id-type="pmid">29260225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130662.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toms</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Nicholas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ram</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.</article-title>
            <source>J Neurooncol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>141</volume>
            <issue>2</issue>
            <fpage>467</fpage>
            <page-range>467-473</page-range>
            <pub-id pub-id-type="pmid">30506499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130662.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turner</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Gergel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lacroix</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toms</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF&#x02122;-100A system.</article-title>
            <source>World J Surg Oncol</source>
            <year>2014</year>
            <month>May</month>
            <day>22</day>
            <volume>12</volume>
            <fpage>162</fpage>
            <pub-id pub-id-type="pmid">24884522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130662.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trusheim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dunbar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Battiste</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Iwamoto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mohile</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Damek</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bota</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Connelly</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma.</article-title>
            <source>CNS Oncol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-43</page-range>
            <pub-id pub-id-type="pmid">27628854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130662.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacouture</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Elzinga</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Butowski</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Villano</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>DiMeglio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>ET</given-names>
              </name>
            </person-group>
            <article-title>Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.</article-title>
            <source>Semin Oncol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>41 Suppl 4</volume>
            <fpage>S1</fpage>
            <page-range>S1-14</page-range>
            <pub-id pub-id-type="pmid">24794308</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
